Guangdong Biolight Meditech Co., Ltd.

Total Valuation

Guangdong Biolight Meditech Co., Ltd. carries a market capitalization of 3.88B, placing it among publicly traded companies globally. Its enterprise value stands at 2.24B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Guangdong Biolight Meditech Co., Ltd. currently has 264.58M shares outstanding.

Valuation Ratios

The price-to-sales ratio is 2.02, and the price-to-book ratio stands at 3.02.

Enterprise Valuation

On an enterprise value basis, Guangdong Biolight Meditech Co., Ltd. trades at an EV/EBITDA multiple of 89.20 and an EV/FCF ratio of 12.26. The EV/Sales ratio of 2.14 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 89.20 provides insight into valuation relative to core operating earnings.

Financial Position

Guangdong Biolight Meditech Co., Ltd. maintains a current ratio of 2.19, meaning it holds 2.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 49.34, indicating elevated leverage, while an interest coverage ratio of -1.12 demonstrates limited ability to service its debt obligations.

Financial Efficiency

Taxes

Over the trailing twelve months, Guangdong Biolight Meditech Co., Ltd. has paid -841,978.20 in income taxes, reflecting an effective tax rate of 0.76.

Stock Price Statistics

Guangdong Biolight Meditech Co., Ltd.'s stock has gained approximately 47.23618% over the past 52 weeks. The 50-day moving average sits at 17.58, while the 200-day moving average is 12.79.

Income Statement

Over the trailing twelve months, Guangdong Biolight Meditech Co., Ltd. generated 1.05B in revenue and converted that into -67.61M in net income, yielding earnings per share of -0.24. EBITDA reached -30.35M, while operating income came in at -30.35M.

Balance Sheet

Guangdong Biolight Meditech Co., Ltd. holds 585.89M in cash and equivalents against 639.31M in total debt, resulting in a net debt position of 2.27M. Total book value stands at 701.16M, with working capital of 642.30M providing operational flexibility.

Cash Flow

After subtracting -156.19M in capital expenditures, free cash flow totaled -156.19M - equivalent to -0.59 per share.

Margins

Guangdong Biolight Meditech Co., Ltd. operates with a gross margin of 26.03, reflecting its pricing power and cost economics. The operating margin of -2.90 and net profit margin of -6.46 provide insight into operational efficiency.

Dividends & Yields

The company's payout ratio of -20.49 indicates the proportion of earnings distributed to shareholders.

Stock Splits

Guangdong Biolight Meditech Co., Ltd.'s most recent stock split took place on May 25, 2023 with a 2:3 split ratio.

Scores

Guangdong Biolight Meditech Co., Ltd. posts an Altman Z-Score of 2.17, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.